

**Improving peer review of in vivo research proposals:  
NC3Rs/BBSRC/CRUK/MRC/Wellcome workshop, 9 May 2018**

**Improving bench-to-bedside translation**

*Professor Ulrich Dirnagl (Charité)*

- Benatar M (2007). Lost in translation: treatment trials in the SOD1 mouse and in human ALS. *Neurobiology of Disease* 26(1): 1-13. doi: 10.1016/j.nbd.2006.12.015
- Blümel C, Gauch S, Hendriks B, Krüger AK, Reinhart M (2015) In Search of Translational Research. iFQ-BIH Report, January 2015. <http://bit.ly/2jtXKBg>
- Blümel C, Gauch S, Krüger AK (2016) Organising Translational Research. DZHW-BIH Report No.2, January 2016 <http://bit.ly/2rmoJD4>
- Cummings JL, Morstorf T and Zhong K (2014). Alzheimer's disease drug-development pipeline: few candidates, frequent failures. *Alzheimers Research and Therapy* 6(4): 37. doi: 10.1186/alzrt269
- Jansen SJ, Doevendans PA and Chamuleau SAJ (2014). All preclinical trials should be registered in advance in an online registry. *European Journal of Clinical Investigation* 44(9): 892-893. doi: 10.1111/eci.12299
- Kimmelman J, Mogil JS and Dirnagl U (2014). Distinguishing between exploratory and confirmatory preclinical research will improve translation. *PLoS Biology* 12(5): e1001863. doi: 10.1371/journal.pbio.1001863
- O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH and Howells DW (2006). 1,026 experimental treatments in acute stroke. *Annals of Neurology* 59(3): 467-477. doi: 10.1002/ana.20741
- Wieschowski S, Chin WWL, Federico C, Sievers S, Kimmelman J and Strech D (2018). Preclinical efficacy studies in investigator brochures: Do they enable risk-benefit assessment? *PLoS Biology* 16(4): doi: ARTN e2004879 10.1371/journal.pbio.2004879